Combination Chemotherapy Plus Fluoxetine in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

Exclusion Criteria

• •3. Measurable or Non-Measurable Disease
• •* Measurable Disease: Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as ≥ 20 mm with conventional techniques or as ≥ 10 mm with spiral CT scan.
• •Lesions that are considered non-measurable include the following:
• •* Bone lesions
• •* Leptomeningeal disease
• •* Ascites
• •* Pleural/pericardial effusion
• •* Abdominal masses that are not confirmed and followed by imaging techniques
• •* Cystic lesions
• •4. Prior Treatment:
• •* No prior chemotherapy.
• •* ≥ 2 weeks since radiation therapy.
• •* No antidepressant treatment (eg, selective serotonin reuptake inhibitors, tricyclics, novel antidepressants, St. John's Wort or monoamine oxidase inhibitors) currently or within the last month.
• •5. If the patient requires pain medication, pain must be managed with non-codeine preparations, including but not limited to: acetaminophen, any morphine based preparation (short or long acting), hydromorphone, fentanyl, levorphanol or methadone.
• •6. CTC Performance Status 0-1.
• •7. Non-pregnant and non-nursing because of significant risk to the fetus/infant.
• •8. Required Initial Laboratory Data:
• •* Granulocytes ≥ 1,500/µl
• •* Platelet count ≥ 100,000/µl
• •* Serum creatinine ≤ 1.5 mg/dl or Calculated CrCl ≥ 60 ml/min
• •* Bilirubin ≤ 2.0 x Upper Limit of Normal (ULN)
• •* Serum glutamic oxaloacetic transaminase (SGOT) ≤ 2.0 x ULN